Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
J Cell Biochem. 2018 Jan;119(1):213-222. doi: 10.1002/jcb.26136. Epub 2017 Jul 4.
Breast cancer (BC) is the most commonly diagnosed cancer in women. The PI3K/AKT/mTOR pathway is among the most frequently dysregulated pathways in patients with BC. The activation of this pathway is associated with increased cell growth and clinical outcome, and its overexpression is associated with a poor prognosis. It has been proposed that it may be of importance as a potential therapeutic target in the treatment of BC. The aim of current review is to provide an overview of the potential utility of PI3K/Akt/mTOR inhibitors in patients with BC, with particular emphasis on recent preclinical and clinical studies. J. Cell. Biochem. 119: 213-222, 2018. © 2017 Wiley Periodicals, Inc.
乳腺癌（BC）是女性最常见的癌症。PI3K/AKT/mTOR 通路是 BC 患者中最常失调的通路之一。该通路的激活与细胞生长增加和临床结局相关，其过度表达与预后不良相关。有人提出，它可能作为 BC 治疗的潜在治疗靶点很重要。本综述的目的是概述 PI3K/Akt/mTOR 抑制剂在 BC 患者中的潜在应用，特别强调最近的临床前和临床研究。J. 细胞。生物化学。119:213-222，2018. © 2017 Wiley Periodicals, Inc.
Zotero 插件